Incannex Healthcare Inc., a clinical-stage pharmaceutical company, has announced new findings from its RePOSA Phase 2 trial of IHL-42X, a treatment for obstructive sleep apnoea (OSA). The study revealed that 57.6% of participants perceived an improvement in their OSA, with 89.5% of those reporting that the change was meaningful to their lives. Reported benefits included enhanced sleep quality, reduced daytime sleepiness, and fewer cognitive disturbances. These results, collected through structured exit interviews, highlight the potential of IHL-42X to improve both clinical and patient-centric outcomes. The exit interviews were conducted before unblinding and included subjects from placebo, low-dose IHL-42X, and high-dose IHL-42X trial arms. The company has not specified a future date for presenting these findings in a formal publication or conference.